Cutia Therapeutics (HK:2487) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cutia Therapeutics has announced that its CFO and Executive Director, Mr. Huang Yuqing, has demonstrated his confidence in the company by purchasing 50,000 additional shares with personal funds. The transaction, with an average price of HK$14.954 per share, suggests a strong belief in the firm’s future. The company reassured that it maintains compliance with public float requirements as per Hong Kong Stock Exchange rules.
For further insights into HK:2487 stock, check out TipRanks’ Stock Analysis page.